NCT01757483

Brief Summary

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
244

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 18, 2012

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 31, 2012

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

December 9, 2015

Status Verified

December 1, 2015

Enrollment Period

2.1 years

First QC Date

December 18, 2012

Last Update Submit

December 8, 2015

Conditions

Acute Coronary Syndrome

Outcome Measures

Primary Outcomes (1)

  • KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)

    2 months

Secondary Outcomes (3)

  • KAU Questionnaire: Practice characteristics

    2 months

  • KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns

    2 months

  • KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.

    2 months

Study Arms (1)

Prescribers

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All physicians who have prescribed at least one dose of ticargrelor and complete the Knowledge and understanding survey

You may qualify if:

  • \- N/A (All prescribers will be contacted for participation)

You may not qualify if:

  • \- Participation in a previous wave of the survey.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Research Site

Montreal, Quebec, Canada

Location

Related Links

MeSH Terms

Conditions

Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Yola Moride, PhD

    Université de Montréal

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2012

First Posted

December 31, 2012

Study Start

November 1, 2012

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

December 9, 2015

Record last verified: 2015-12

Locations

CA(1)